Intercellular Adhesion Molecule Inhibitors as Potential Therapy for Refractory Uveitic Macular Edema

Basit Öğe Kaydı
dc.authoridturkcuoglu, peykan/0000-0002-9750-6213
dc.authorwosidwang, jian/GVS-0711-2022
dc.authorwosidIbrahim, Mohamed Fahmy/AAP-7467-2021
dc.authorwosidturkcuoglu, peykan/GQB-2596-2022
dc.authorwosidNguyen, Truong/JXN-9786-2024
dc.authorwosidNguyen, Quan/JMP-5630-2023
dc.authorwosidC, Roomasa/AAK-5176-2020
dc.authorwosidC, R/HJA-9099-2022
dc.contributor.authorWang, Jianmin
dc.contributor.authorIbrahim, Mohamed
dc.contributor.authorTurkcuoglu, Peykan
dc.contributor.authorHatef, Elham
dc.contributor.authorKhwaja, Afsheen
dc.contributor.authorChanna, Roomasa
dc.contributor.authorDo, Diana V.
dc.date.accessioned2024-08-04T20:32:32Z
dc.date.available2024-08-04T20:32:32Z
dc.date.issued2010
dc.departmentİnönü Üniversitesien_US
dc.description.abstractPurpose: To describe the bioactivity of an intercellular adhesion molecule inhibitor (efalizumab) in a patient with refractory uveitic macular edema. Methods: A 55-year-old man presented with idiopathic autoimmune uveitis and associated macular edema, which could not be controlled by regional and systemic corticosteroid and selected immunomodulatory therapy. Efalizumab was administered as subcutaneous injections. Results: After 37 weekly injections of efalizumab, the uveitic macular edema was successfully eliminated. Six months following discontinuation of efalizumab, there were no signs of recurrent inflammation. Conclusion: Further investigation of the role of intercellular adhesion molecule inhibitors in the management of uveitic macular edema is indicated.en_US
dc.description.sponsorshipChinese Ophthalmological Society; Research to Prevent Blindness Foundationen_US
dc.description.sponsorshipDr. Wang is a recipient of the Kangzhe Advanced Study Abroad Scholarship from the Chinese Ophthalmological Society. Dr. Nguyen is a recipient of a Physician Scientist Award from the Research to Prevent Blindness Foundation.en_US
dc.identifier.doi10.3109/09273948.2010.483317
dc.identifier.endpage398en_US
dc.identifier.issn0927-3948
dc.identifier.issn1744-5078
dc.identifier.issue5en_US
dc.identifier.pmid20666682en_US
dc.identifier.scopus2-s2.0-77956828128en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage395en_US
dc.identifier.urihttps://doi.org/10.3109/09273948.2010.483317
dc.identifier.urihttps://hdl.handle.net/11616/95134
dc.identifier.volume18en_US
dc.identifier.wosWOS:000283482600014en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofOcular Immunology and Inflammationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectICAM inhibitoren_US
dc.subjectmacular edemaen_US
dc.subjectuveitisen_US
dc.titleIntercellular Adhesion Molecule Inhibitors as Potential Therapy for Refractory Uveitic Macular Edemaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu